

		<del></del>		<del></del>
A. CLASS INV.	CO7K14/315 A61K39/09 A61K38/	7088 A61K	39/40	
According t	to International Patent Classification (IPC) or to both national classifi	ation and IPC		
B. FIELDS	SEARCHED			
Minimum d	ocumentation searched (classification system followed by classifica $A61K$	on symbols)		
	ation searched other than minimum documentation to the extent that			
	data base consulted during the international search (name of data b			
EPO-1n	iternal, BIOSIS, EMBASE, WPI Data, P	AJ, Sequenc	e Search	
C. DOCUM	ENTS CONSIDERED TO BE RELEVANT	<u> </u>		
Category*	Citation of document, with indication, where appropriate, of the re	evant passages	Rele	evant to claim No.
		-/		
1 - 2				
X Furt	her documents are listed in the continuation of Box C.	X See patent	family annex.	
	categories of cited documents:	"T" later document or priority date	published after the international fili and not in conflict with the applica	ing date
consid	ent defining the general state of the art which is not dered to be of particular relevance document but published on or after the international	cited to unders invention	tand the principle or theory under	lying the
filing of the filling	date ent which may throw doubts on priority claim(s) or		rticular relevance; the claimed investigation in the consider of the consideration in the consideration in the count is the count in th	
citatio	is cited to establish the publication date of another on or other special reason (as specified)	"Y" document of pa	rticular relevance; the claimed investigation investigation involve an inventive step ombined with one or more other se	ention p when the
"O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed		ments, such coin the art.	bmbination being obvious to a personer of the same patent family	
	actual completion of the international search	Date of mailing	of the international search report	
2	2 February 2006	2	0. 06. 2006	
Name and	mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2	Authorized office	er	
	NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016	Mauhi	n, V	



Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X .	WO 2004/078907 A (INTERCELL AG; MEINKE, ANDREAS; NAGY, ESZTER; WINKLER, BIRGIT; GELBMANN) 16 September 2004 (2004-09-16) page 9, line 49 - page 10, line 21 page 12, line 15 - line 16 page 14, line 3 - line 4 page 22, line 32 - line 39 page 24, line 4 - line 5 page 31, line 31 - page 32, line 22 page 35, line 50 - page 37, line 28 page 39, line 16 - line 30 page 40, line 8 - line 22 spy0019 of SEQ. ID. No. 152 is 100% identical to present GAS5 (SEQ. ID. No. 2). Specific epitopes are disclosed. The encoding DNA of SEQ. ID. No. 2 is 100% identical to present GAS5 (SEQ. ID. No. 651) figure 4a; example 5; tables 1,3	1-40
X	DATABASE UniProt [Online] 1 October 2002 (2002-10-01), XP002367841 retrieved from EBI Database accession no. Q8P318	1,24
X	the whole document  -& NAKAGAWA ICHIRO ET AL: "Genome sequence of an M3 strain of Streptococcus pyogenes reveals a large-scale genomic rearrangement in invasive strains and new insights into phage evolution." GENOME RESEARCH, vol. 13, no. 6a, June 2003 (2003-06), pages 1042-1055, XP002367632 ISSN: 1088-9051 protein SPS0015 SPYM3_0014 is 99,497% identical to present GAS5 over the whole sequence.	1,24
X	DATABASE UniProt [Online] 5 July 2004 (2004-07-05), XP002367842 retrieved from EBI Database accession no. Q7CNQ7 the whole document -/	1,24

## IN RNATIONAL SEARCH REPORT



Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	-& SMOOT J C ET AL: "Genome sequence and comparative microarray analysis of serotype M18 group A Streptococcus strains associated with acute rheumatic fever outbreaks" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 99, no. 7, 2 April 2002 (2002-04-02), pages 4668-4673, XP002267116 ISSN: 0027-8424 SPYM18_0020 is 99,497% identical to present GAS5 over the whole sequence	1,24
Ρ,Χ	DATABASE UniProt [Online] 23 November 2004 (2004-11-23), XP002367843 retrieved from EBI Database accession no. Q5XEL1 the whole document	1,24
X	-& BANKS D J ET AL: "PROGRESS TOWARD CHARACTERIZATION OF THE GROUP A STREPTOCOCCUS METAGENOME: COMPLETE GENOME SEQUENCE OF A MACROLIDE-RESISTANT SEROTYPE M6 STRAIN" JOURNAL OF INFECTIOUS DISEASES, CHICAGO, IL, US, vol. 190, no. 4, 15 August 2004 (2004-08-15), pages 727-738, XP008047099 ISSN: 0022-1899 M6_SPY0017 is 99,497% identical to present GAS5 over the whole sequence	1,24
A	FERRETTI J J ET AL: "Complete genome sequence of an M1 strain of Streptococcus pyogenes" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 98, no. 8, 10 April 2001 (2001-04-10), pages 4658-4663, XP002168716 ISSN: 0027-8424	
A	OLIVE C ET AL: "Protection of mice from group A streptococcal infection by intranasal immunisation with a peptide vaccine that contains a conserved M protein B cell epitope and lacks a T cell autoepitope" VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 20, no. 21-22, 21 June 2002 (2002-06-21), pages 2816-2825, XP004357806 ISSN: 0264-410X	

International application No. PCT/US2005/036009

### INTERNATIONAL SEARCH REPORT

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
<ol> <li>χ Claims Nos.: –</li> <li>because they relate to subject matter not required to be searched by this Authority, namely:</li> </ol>
Although claims 37 and 38 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
see additional sheet
1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
A. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  1-40 (all partially)
Remark on Protest  The additional search fees were accompanied by the applicant's protest.  No protest accompanied the payment of additional search fees.

#### FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

Inventions 1-68: claims 1-40 (all partially)

Subject-matter relating to one of the GAS proteins listed in Table 2 in the apparition order in said Table 2, i.e. GAS antigen 5, 6, 18, 22, 23, 25, 29, 30, 36, 49, 56, 60, 62, 63, 65, 67, 68, 69, 74, 75, 76, 77, 78, 81, 82, 85, 86, 89, 91, 92, 93, 94, 96, 97, 98, 99, 100, 101, 103, 104, 105, 108, 123, 131, 142, 143, 158, 165, 166, 175, 178, 179, 187, 188, 190, 195, 205, 206, 207, 218, 219, 242, 249, 271, 291, 327, 380, 685, respectively, as well as to fragments and homologues of said sequences (e.g. GRAB precursor and SPs1285 of Table 11) and to the encoding nucleic acid sequences and antibodies directed to said proteins.

Inventions 69-73: claims 1-40 (all partially)

Subject-matter relating to one of the GAS proteins listed in Table 3 not mentioned in Table 2, in the apparition order in said Table 3, i.e. GAS 73, 74, 109, 129, 130, respectively, as well as to fragments and homologues of said sequence and to the encoding nucleic acid sequences and antibodies directed to said proteins.

Invention 74: claims 1-40 (all partially)

Subject-matter relating to one of the GAS40 protein, in native form or as fusion protein as found in Table 4A-R as well as to fragments and homologues thereof (e.g. as found in Table 5), and to the encoding nucleic acid sequences and antibodies directed to said proteins.

Inventions 75-137: claims 1-40 (all partially)

Subject-matter relating to one of the GAS proteins listed in Table 7 not previously mentioned, in the apparition order in said Table 7, i.e. GAS 4, 15, 16, 24, 54, 57, 64, 72, 84, 102, 152, 157, 163, 168, 177, 191, 192, 193, 194, 198, 201, 224, 251, 259, 262, 264, 268, 277, 282, 299, 382, 405, 406, 425, 433, 460, 469, 493, 500, 545, 558, 587, 645, 650, 362-1, SPY0080a, 0272, 0461, 0611, 0717, 0792, 1029, 1073, 1260, 1613, 1835, 2005, 2093, 2178, GAS45, SPY0047, 0127, 0686, respectively, as well as to fragments and homologues thereof (e.g. M protein type 3 and C5A peptidase precursor of Table 11) and to the encoding nucleic acid sequences and antibodies directed to said proteins.

Inventions 138-160: claims 1-40 (all partially)

#### FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Subject-matter relating to one of the GAS proteins listed in Table 8 not previously mentioned, in the apparition order in said Table 8, i.e. GAS10, 83, 160, 284, 286, 292, 396, SPY0053, 0056, 0063, 0069, 0098, 0666, 0688, 0913, 1200, 1281, 1721, 1750, 1805, 2070, 2092 and g-21909751, respectively, as well as to fragments and homologues thereof and to the encoding nucleic acid sequences and antibodies directed to said proteins.

Inventions 161-162: claims 1-40 (all partially)

Subject-matter relating to one of the GAS proteins listed in Table 9 not mentioned previously, in the apparition order in said Table 9, i.e. NTO1SP0246 and GAS309, respectively, as well as to fragments and homologues thereof and to the encoding nucleic acid sequences and antibodies directed to said proteins.

Inventions 163-165: claims 1-40 (all partially)

Subject-matter relating to GAS proteins listed in Table 11 not mentioned previously in apparition order in said Table 11, i.e. SPY1664, GAS149 and SPY0861, respectively, and to fragments and homologues thereof (e.g. putative penicillin binding proteins 2X, putative large conductance mechanosensitive channel and hypothetical protein SPs1270 found in Table 11), and to the encoding nucleic acid sequences and antibodies directed to said proteins.

Inventions 166-180: claims 1-40 (all partially)

Subject-matter relating to the proteins listed in Table 12 considering the references given.

Inventions 181-207: claims 1-40 (all partially)

Subject-matter relating to one of the GAS proteins listed in Table 15 not mentioned previously in the apparition order in said Table 15, i.e. GAS35, 414, 426, 434, 437, 438, 439, 461, 465, 472, 473, 475, 477, 478, 495, 538, 543, 553, 561, 576, 577, 591, 592, 636, 643, 649, 663, respectively, as well as to fragments and homologues thereof, the encoding nuceic acid sequences and antibodies directed to said proteins.

Inventions 208-236: claims 1-40 (all partially)

#### FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Subject-matter relating to the GAS proteins listed in Table 16 not mentioned previously in apparition order of said Table 16, i.e. GAS42, GAS95, M30098, M3\_0100, M3\_0102, M3\_0104, SPs0106, GAS130, GAS137, M6\_0157, M6\_0159, GAS159, M6\_0160, GAS217, 220, 290, 294, 384, 504, 509, 511, 527, 529, 533, 680, 19224134, 19224135, 19224137, 19224141, respectively, as well as to fragments and homologues thereof, the encoding nucleic acid sequences and antibodies directed to said proteins.

Inventions 237-272: claims 1-40 (all partially)

Subject-matter relating to one of the GAS proteins not previously mentioned in the Tables but cited in the claims, in the apparition order in said claims, i.e. NT01SP0102, NT01SP0908 (SPY1111), NT01SP0182 (SPY0216), GAS70, 421, 428, 457, 474, 486, 492, 494, 535, 540, 560, 564, 565, 574, 579, 586, 607, 609, 625, 626, 640, 653, 657, 39, 58, 236, 366, 372, 389, Mprotein, SagA, Sfb1, Shp, respectively, as well as to fragments and homologues thereof, the encoding nucleic acid sequences and antibodies directed to said proteins.

Inventions 273-275: claim 36, partially

Subject-matter relating to the use of an antibody in the manufacture of a medicament for treating S. pyrogenes infection, wherein the antibody specifically binds to a surface-exposed GAS antigen which is shorter by at least one amino acid than a GAS protein listed in Table 1 which was not previously mentioned, i.e. GAS41, GAS183 and GAS202, respectively.

# IN RNATIONAL SEARCH REPORT

Information on patent family members

International application No PCT/US2005/036009

					PC1/U32	005/036009
Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 2004078907	Α	16-09-2004	AU CA	2004218284 2517518		16-09-2004 16-09-2004
				· · · · · · · · · · · · · · · · · · ·		·